8RP Stock Overview
Celon Pharma S.A., an integrated pharmaceutical company, engages in the research, manufacture, and marketing of pharmaceutical products and preparations.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 8RP from our risk checks.
Celon Pharma S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł3.30 |
| 52 Week High | zł3.90 |
| 52 Week Low | zł2.95 |
| Beta | 0.80 |
| 1 Month Change | -2.66% |
| 3 Month Change | -1.49% |
| 1 Year Change | 11.69% |
| 3 Year Change | -67.88% |
| 5 Year Change | n/a |
| Change since IPO | -66.51% |
Recent News & Updates
Recent updates
Shareholder Returns
| 8RP | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 1.2% | 2.3% | 0.5% |
| 1Y | 11.7% | -28.6% | 1.3% |
Return vs Industry: 8RP exceeded the German Pharmaceuticals industry which returned -28.2% over the past year.
Return vs Market: 8RP exceeded the German Market which returned 2.3% over the past year.
Price Volatility
| 8RP volatility | |
|---|---|
| 8RP Average Weekly Movement | 3.7% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 8RP has not had significant price volatility in the past 3 months.
Volatility Over Time: 8RP's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 513 | Maciej Wieczorek | www.celonpharma.com |
Celon Pharma S.A., an integrated pharmaceutical company, engages in the research, manufacture, and marketing of pharmaceutical products and preparations. It offers drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. The company was founded in 2002 and is based in Lomianki, Poland.
Celon Pharma S.A. Fundamentals Summary
| 8RP fundamental statistics | |
|---|---|
| Market cap | €176.91m |
| Earnings (TTM) | -€6.51m |
| Revenue (TTM) | €50.16m |
3.5x
P/S Ratio-27.2x
P/E RatioIs 8RP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8RP income statement (TTM) | |
|---|---|
| Revenue | zł216.57m |
| Cost of Revenue | zł66.82m |
| Gross Profit | zł149.75m |
| Other Expenses | zł177.87m |
| Earnings | -zł28.12m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 22, 2024
| Earnings per share (EPS) | -0.55 |
| Gross Margin | 69.15% |
| Net Profit Margin | -12.99% |
| Debt/Equity Ratio | 2.9% |
How did 8RP perform over the long term?
See historical performance and comparison